Retraction
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
Paper Information
Record ID:
36208
Author(s):
Journal:
Publication Date:
June 01, 2018
Retraction Date:
March 15, 2022
(3.7 years years ago)
Subjects:
Broad Categories:
Biology
Biology
Institutions:
- Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
- Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Division of Cell Biology, Biomedical Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan
- Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Tokyo, Japan
- Gordon and Jessie Gilmour Leukaemia Research Laboratory, Immunology Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- The Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
- School of Medicine, The University of Queensland, Herston, Queensland, Australia
- Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
- Immuno-oncology Discovery, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
Country:
🇦🇺 AustraliaArticle Type:
Publisher:
American Society for Clinical Investigation
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1172/JCI159825Additional Notes:
Mark Smyth has insitutional finding of misconduct
Citations (102)
102
Total Citations28
Post-Retraction(27.5%)
74
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
2
Within 30 days
15
Within 1 year
9
After 2+ years
1140
Days since retraction (latest)
Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families
Yizhi Liu, Xinyan Jiang, Ruijuan Dong et al. (6 authors)
Frontiers in Immunology
Open Access
Published: Apr 2025
1140 days after retraction
Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies
Daosong Dong, Yu Xue, Haoran Liu et al. (11 authors)
Seminars in Cancer Biology
Published: Feb 2025
1 citation
1 citation
1054 days after retraction
CD155 promotes the progression of colorectal cancer by restraining CD8+ T cells via the PI3K/AKT/NF-κB pathway
Rongpu Liang, Liting Liu, Dongbing Ding et al. (6 authors)
Cancer Immunology Immunotherapy
Open Access
Published: Feb 2025
1054 days after retraction
Paper citing CD155 loss enhances tumor suppression via combined...
Unknown Authors
Unknown Journal
Published: Nov 2024
969 days after retraction
Clinical significance of CD155 expression in surgically resected lung squamous cell carcinoma
Taichi Nagano, Kazuki Takada, Asato Hashinokuchi et al. (11 authors)
International Journal of Clinical Oncology
Published: Oct 2024
1 citation
1 citation
953 days after retraction
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang et al. (8 authors)
Signal Transduction and Targeted Therapy
Open Access
Published: May 2024
26 citations
26 citations
799 days after retraction
Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling
Li-Ying Wu, Su-Ho Park, Haakan Jakobsson et al. (5 authors)
Cancers
Open Access
Published: May 2024
1 citation
1 citation
798 days after retraction
Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy – obstacles and perspectives
Jiřina Procházková, Zuzana Kahounová, Jan Vondráček et al. (4 authors)
Transcription
Published: Mar 2024
5 citations
5 citations
744 days after retraction
CD155 as an emerging target in tumor immunotherapy
Jiang‐Wan Wu, Ying Liu, Xing‐Jie Dai et al. (6 authors)
International Immunopharmacology
Published: Mar 2024
3 citations
3 citations
738 days after retraction
Relationship between expression of CD155 and TIGIT and clinicopathological features in gastrointestinal neuroendocrine tumors
Wei Xie, Song Yu, Nengyi Hou et al. (10 authors)
Shijie huaren xiaohua zazhi
Open Access
Published: Feb 2024
715 days after retraction
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Wonyoung Jo, Taejoon Won, Abdel Daoud et al. (4 authors)
Frontiers in Immunology
Open Access
Published: Feb 2024
17 citations
17 citations
692 days after retraction
ADAR-mediated RNA editing regulates PVR immune checkpoint in colorectal cancer
Cheng-Jia Qian, Yu-Shan He, Tao Guo et al. (8 authors)
Biochemical and Biophysical Research Communications
Published: Dec 2023
1 citation
1 citation
638 days after retraction
Studying TIGIT activity against tumors through the generation of knockout mice
Ahmed Rishiq, Reem Bsoul, Ophir Pick et al. (4 authors)
OncoImmunology
Open Access
Published: May 2023
11 citations
11 citations
440 days after retraction
Single-cell biological network inference using a heterogeneous graph transformer
Anjun Ma, Xiaoying Wang, Jingxian Li et al. (20 authors)
Nature Communications
Open Access
Published: Feb 2023
105 citations
105 citations
343 days after retraction
Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors
Shovan Dutta, Anirban Ganguly, Kaushiki Chatterjee et al. (5 authors)
Biology
Open Access
Published: Jan 2023
80 citations
80 citations
321 days after retraction
Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Hayden Pearce, Wayne Croft, Samantha M. Nicol et al. (16 authors)
Cancer Immunology Research
Open Access
Published: Jan 2023
43 citations
43 citations
314 days after retraction
The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
Anna Pawłowska, Wiktoria Skiba, Dorota Suszczyk et al. (7 authors)
Cancers
Open Access
Published: Nov 2022
19 citations
19 citations
253 days after retraction
Advancements in Polymeric Nanocarriers to Mediate Targeted Therapy against Triple-Negative Breast Cancer
Mahak Fatima, Afsana Sheikh, Mohammed A. S. Abourehab et al. (4 authors)
Pharmaceutics
Open Access
Published: Nov 2022
25 citations
25 citations
240 days after retraction
Cancer fitness genes: emerging therapeutic targets for metastasis
Minhong Shen, Yibin Kang
Trends in cancer
Open Access
Published: Sep 2022
6 citations
6 citations
199 days after retraction
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives
Pooya Farhangnia, Mahzad Akbarpour, Mahboubeh Yazdanifar et al. (6 authors)
Expert Review of Clinical Immunology
Published: Sep 2022
10 citations
10 citations
195 days after retraction
V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy
Xia Zhou, Sohail Khan, Dabing Huang et al. (4 authors)
Frontiers in Immunology
Open Access
Published: Sep 2022
25 citations
25 citations
184 days after retraction
The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition
A. Yu. Kuzevanova, Н. В. Апанович, Danzan Mansorunov et al. (5 authors)
Biomedicines
Open Access
Published: Aug 2022
8 citations
8 citations
163 days after retraction
The role of the natural killer (NK) cell modulation in breast cancer incidence and progress
Ehsan Razeghian, Mahdis Chahar Kameh, Sepehr Shafiee et al. (10 authors)
Molecular Biology Reports
Published: Aug 2022
15 citations
15 citations
163 days after retraction
CD155 promotes radioresistance and malignancy of esophageal cancer by regulating Hippo-YAP pathway
Huixian Xin, Yuchen Liu, Pengxiang Chen et al. (8 authors)
Discover Oncology
Open Access
Published: Jun 2022
6 citations
6 citations
106 days after retraction
Emergence of the CD226 Axis in Cancer Immunotherapy
Michael Conner, Ken W. Hance, Sapna Yadavilli et al. (5 authors)
Frontiers in Immunology
Open Access
Published: Jun 2022
24 citations
24 citations
101 days after retraction
What Inhibits Natural Killers’ Performance in Tumour
Ines Papak, Elżbieta Chruściel, Katarzyna Dziubek et al. (8 authors)
International Journal of Molecular Sciences
Open Access
Published: Jun 2022
8 citations
8 citations
101 days after retraction
CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis
Anli Jin, Chunyan Zhang, Wenjing Zheng et al. (18 authors)
Clinical and Translational Medicine
Open Access
Published: Apr 2022
29 citations
29 citations
17 days after retraction
Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
Daijun Wang, Yanmei Gu, Xin Yan et al. (8 authors)
Frontiers in Oncology
Open Access
Published: Mar 2022
21 citations
21 citations
15 days after retraction
CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer
Chang Jiang, Xiaodie Qu, Li Ma et al. (10 authors)
Clinical & Experimental Immunology
Open Access
Published: Mar 2022
12 citations
12 citations
6 days before retraction
Blocking TIGIT/CD155 Signal Reverses CD8+T Cell Exhaustion and Enhances the Anti-Tumor Ability of Cervical Cancer
Lu Liu, Aihong Wang, Xiaoli Liu et al. (8 authors)
Research Square (Research Square)
Open Access
Published: Feb 2022
15 days before retraction
Recent Advances in the Therapeutic Efficacy of Artesunate
Ngonidzashe Ruwizhi, Rejoice B. Maseko, Blessing A. Aderibigbe
Pharmaceutics
Open Access
Published: Feb 2022
36 citations
36 citations
18 days before retraction
Functional visualization of NK cell-mediated killing of metastatic single tumor cells
Hiroshi Ichise, Shoko Tsukamoto, Tsuyoshi Hirashima et al. (11 authors)
eLife
Open Access
Published: Feb 2022
48 citations
48 citations
41 days before retraction
The Pyroptosis-Related Gene Signature Predicts the Prognosis of Hepatocellular Carcinoma
Shuqiao Zhang, Xinyu Li, Xiang Zhang et al. (6 authors)
Frontiers in Molecular Biosciences
Open Access
Published: Jan 2022
17 citations
17 citations
71 days before retraction
Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis
Danzan Mansorunov, Н. В. Апанович, П. В. Апанович et al. (9 authors)
Diagnostics
Open Access
Published: Dec 2021
9 citations
9 citations
89 days before retraction
TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas
Xiuning Le, Minghao Dang, Venkatesh L. Hegde et al. (26 authors)
medRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Dec 2021
1 citation
1 citation
100 days before retraction
Crosstalk between macrophages and natural killer cells in the tumor microenvironment
Jingping Zhou, Shaolong Zhang, Changying Guo
International Immunopharmacology
Published: Nov 2021
47 citations
47 citations
113 days before retraction
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
Shusuke Kawashima, Takashi Inozume, Masahito Kawazu et al. (21 authors)
Journal for ImmunoTherapy of Cancer
Open Access
Published: Nov 2021
56 citations
56 citations
117 days before retraction
DeepMAPS: Single-cell biological network inference using heterogeneous graph transformer
Anjun Ma, Xiaoying Wang, Cankun Wang et al. (19 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Nov 2021
9 citations
9 citations
132 days before retraction
CD155: A Key Receptor Playing Diversified Roles
Shyam Sundar Nandi, Trupti Gohil, Sonali Sawant et al. (6 authors)
Current Molecular Medicine
Published: Sep 2021
15 citations
15 citations
183 days before retraction
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
Hasan Baysal, Ines De Pauw, Hannah Zaryouh et al. (8 authors)
Frontiers in Immunology
Open Access
Published: Sep 2021
49 citations
49 citations
189 days before retraction
BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer
Mei Feng, Zhongen Wu, Yan Zhou et al. (19 authors)
Signal Transduction and Targeted Therapy
Open Access
Published: Aug 2021
32 citations
32 citations
207 days before retraction
Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review)
Khalil Choucair, Maluki Radford, Ajay Bansal et al. (5 authors)
International Journal of Oncology
Open Access
Published: Aug 2021
10 citations
10 citations
216 days before retraction
TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells
Liang Mao, Yao Xiao, Qi‐Chao Yang et al. (6 authors)
Oral Oncology
Published: Jul 2021
51 citations
51 citations
228 days before retraction
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
Zhouhong Ge, Maikel P. Peppelenbosch, Dave Sprengers et al. (4 authors)
Frontiers in Immunology
Open Access
Published: Jul 2021
174 citations
174 citations
236 days before retraction
Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis
Chuanrong Chen, Qianqian Guo, Hao Fu et al. (8 authors)
Biomaterials
Published: Jun 2021
57 citations
57 citations
264 days before retraction
CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways
Lu Liu, Ying Wang, Geng Chen et al. (10 authors)
Frontiers in Oncology
Open Access
Published: Jun 2021
16 citations
16 citations
281 days before retraction
Bioinformatics Profiling of Five Immune-Related lncRNAs for a Prognostic Model of Hepatocellular Carcinoma
Fahong Wu, Hangzhi Wei, Guiyuan Liu et al. (4 authors)
Frontiers in Oncology
Open Access
Published: May 2021
24 citations
24 citations
291 days before retraction
Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226/TIGIT
Jie Zhang, Long Zhou, Jiangdong Xiang et al. (6 authors)
International Immunopharmacology
Published: Apr 2021
26 citations
26 citations
320 days before retraction
Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma
Jii Bum Lee, Min Hee Hong, Sung Yong Park et al. (8 authors)
Scientific Reports
Open Access
Published: Apr 2021
18 citations
18 citations
329 days before retraction
Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer
Fabrizio Marcucci, Cristiano Rumio
Cells
Open Access
Published: Apr 2021
5 citations
5 citations
337 days before retraction
Quick Stats
Total Citations:
102
Years Since Retraction:
3.7 years
Open Access:
Yes
Last Checked:
Jul 24, 2025